125 related articles for article (PubMed ID: 19634111)
1. CHFR promoter hypermethylation and reduced CHFR mRNA expression in ovarian cancer.
Gao Y; Lou G; Zhang GM; Sun XW; Ma YY; Yang YM; Liu G
Int J Biol Markers; 2009; 24(2):83-9. PubMed ID: 19634111
[TBL] [Abstract][Full Text] [Related]
2. Promoter methylation of p16, Runx3, DAPK and CHFR genes is frequent in gastric carcinoma.
Hu SL; Kong XY; Cheng ZD; Sun YB; Shen G; Xu WP; Wu L; Xu XC; Jiang XD; Huang DB
Tumori; 2010; 96(5):726-33. PubMed ID: 21302620
[TBL] [Abstract][Full Text] [Related]
3. Aberrant promoter hypermethylation of the CHFR gene in oral squamous cell carcinomas.
Baba S; Hara A; Kato K; Long NK; Hatano Y; Kimura M; Okano Y; Yamada Y; Shibata T
Oncol Rep; 2009 Nov; 22(5):1173-9. PubMed ID: 19787237
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic inactivation of CHFR in nasopharyngeal carcinoma through promoter methylation.
Cheung HW; Ching YP; Nicholls JM; Ling MT; Wong YC; Hui N; Cheung A; Tsao SW; Wang Q; Yeun PW; Lo KW; Jin DY; Wang X
Mol Carcinog; 2005 Aug; 43(4):237-45. PubMed ID: 15937956
[TBL] [Abstract][Full Text] [Related]
5. Promoter hypermethylation of the Chfr gene in neoplastic and non-neoplastic gastric epithelia.
Honda T; Tamura G; Waki T; Kawata S; Nishizuka S; Motoyama T
Br J Cancer; 2004 May; 90(10):2013-6. PubMed ID: 15138487
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic and genetic silencing of CHFR in esophageal adenocarcinomas.
Soutto M; Peng D; Razvi M; Ruemmele P; Hartmann A; Roessner A; Schneider-Stock R; El-Rifai W
Cancer; 2010 Sep; 116(17):4033-42. PubMed ID: 20564104
[TBL] [Abstract][Full Text] [Related]
7. CHFR: a key checkpoint component implicated in a wide range of cancers.
Sanbhnani S; Yeong FM
Cell Mol Life Sci; 2012 May; 69(10):1669-87. PubMed ID: 22159584
[TBL] [Abstract][Full Text] [Related]
8. Mechanism and pathobiologic implications of CHFR promoter methylation in gastric carcinoma.
Gao YJ; Xin Y; Zhang JJ; Zhou J
World J Gastroenterol; 2008 Aug; 14(32):5000-7. PubMed ID: 18763281
[TBL] [Abstract][Full Text] [Related]
9. [Study of mRNA expression level and hypermethylation of CHFR promoter in the laryngeal squamous cell carcinoma tissue].
He L; Ji W; Yang J; Zhao X
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2010 Aug; 24(15):673-7. PubMed ID: 20942233
[TBL] [Abstract][Full Text] [Related]
10. Checkpoint with forkhead-associated and ring finger promoter hypermethylation correlates with microsatellite instability in gastric cancer.
Oki E; Zhao Y; Yoshida R; Masuda T; Ando K; Sugiyama M; Tokunaga E; Morita M; Kakeji Y; Maehara Y
World J Gastroenterol; 2009 May; 15(20):2520-5. PubMed ID: 19469003
[TBL] [Abstract][Full Text] [Related]
11. Promoter hypermethylation of DNA damage response genes in hepatocellular carcinoma.
Li Z; Zhang H; Yang J; Hao T; Li S
Cell Biol Int; 2012 May; 36(5):427-32. PubMed ID: 21864295
[TBL] [Abstract][Full Text] [Related]
12. Promoter methylation of CHFR gene in gastric carcinoma tissues detected using two methods.
Cheng ZD; Hu SL; Sun YB; Xu WP; Shen G; Kong XY
Chin J Cancer; 2010 Feb; 29(2):163-6. PubMed ID: 20109344
[TBL] [Abstract][Full Text] [Related]
13. CHFR promoter hypermethylation in colon cancer correlates with the microsatellite instability phenotype.
Brandes JC; van Engeland M; Wouters KA; Weijenberg MP; Herman JG
Carcinogenesis; 2005 Jun; 26(6):1152-6. PubMed ID: 15760919
[TBL] [Abstract][Full Text] [Related]
14. Methylation-independent CHFR expression is a potential biomarker affecting prognosis in acute myeloid leukemia.
Zhou JD; Zhang TJ; Li XX; Ma JC; Guo H; Wen XM; Yao DM; Zhang W; Lin J; Qian J
J Cell Physiol; 2018 Jun; 233(6):4707-4714. PubMed ID: 29115660
[TBL] [Abstract][Full Text] [Related]
15. CHFR-Promoter-Methylation Status Is Predictive of Response to Irinotecan-based Systemic Chemotherapy in Advanced Colorectal Cancer.
Hagiwara T; Sugimoto K; Momose H; Irie T; Honjo K; Okazawa YU; Kawai M; Kawano S; Munakata S; Takahashi M; Kojima Y; Serizawa N; Nagahara A; Hoffman RM; Brock MV; Sakamoto K
Anticancer Res; 2022 Feb; 42(2):697-707. PubMed ID: 35093868
[TBL] [Abstract][Full Text] [Related]
16. Emerging evidence for CHFR as a cancer biomarker: from tumor biology to precision medicine.
Derks S; Cleven AH; Melotte V; Smits KM; Brandes JC; Azad N; van Criekinge W; de Bruïne AP; Herman JG; van Engeland M
Cancer Metastasis Rev; 2014 Mar; 33(1):161-71. PubMed ID: 24375389
[TBL] [Abstract][Full Text] [Related]
17. Altered expression of the early mitotic checkpoint protein, CHFR, in breast cancers: implications for tumor suppression.
Privette LM; González ME; Ding L; Kleer CG; Petty EM
Cancer Res; 2007 Jul; 67(13):6064-74. PubMed ID: 17596595
[TBL] [Abstract][Full Text] [Related]
18. Aberrant hypermethylation of the promoter region of the CHFR gene is rare in primary breast cancer.
Tokunaga E; Oki E; Nishida K; Koga T; Yoshida R; Ikeda K; Kojima A; Egashira A; Morita M; Kakeji Y; Maehara Y
Breast Cancer Res Treat; 2006 May; 97(2):199-203. PubMed ID: 16502017
[TBL] [Abstract][Full Text] [Related]
19. CHFR gene is neither mutated nor hypermethylated in ovarian cancer.
Ludwig AH; Bujko M; Bidzinski M; Kupryjańczyk J
Cancer Detect Prev; 2007; 31(3):257-61. PubMed ID: 17673375
[TBL] [Abstract][Full Text] [Related]
20. CHFR suppression by hypermethylation sensitizes endometrial cancer cells to paclitaxel.
Wang X; Yang Y; Xu C; Xiao L; Shen H; Zhang X; Li T; Li X
Int J Gynecol Cancer; 2011 Aug; 21(6):996-1003. PubMed ID: 21792009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
